SKYE — Skye Bioscience Balance Sheet
0.000.00%
- $34.94m
- -$1.08m
Annual balance sheet for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.47 | 8.98 | 1.24 | 1.43 | 70.4 |
| Net Total Receivables | — | — | — | 0.032 | 0.005 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2.66 | 9.61 | 8.94 | 11.7 | 70.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.007 | 0.235 | 0.159 | 0.281 | 1.88 |
| Other Long Term Assets | |||||
| Total Assets | 2.67 | 9.86 | 9.11 | 11.9 | 72.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.787 | 3.91 | 12.1 | 13.9 | 4.34 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.22 | 3.99 | 12.1 | 14.1 | 4.61 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 0.451 | 5.86 | -3.01 | -2.13 | 68.2 |
| Total Liabilities & Shareholders' Equity | 2.67 | 9.86 | 9.11 | 11.9 | 72.8 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |